Incorporating Somatuline’s generic approval headwinds
07/01/22 -"Despite easing pandemic headwinds and recovering underlying markets, our EPS estimates reset lower as we take on board Somatuline’s sales erosion on account of the approval of its generic in the US. ..."
Pages
55
Language
English
Published on
07/01/22
You may also be interested by these reports :
14/10/26
Lonza presented its mid-term outlook at its CMD today in Vacaville (US). The group unveiled ambitious targets, aiming for 10–13% average CER sales ...
14/10/26
Since we last teased Genmab’s (ADD; Denmark) story – a company that specialises in developing antibodies for cancer treatment – in February 2025, the ...
07/10/26
Our estimates are already at the higher end, with our target price significantly benefitting from increased NAV and DCF estimates, as well as a ...
30/09/26
Lundbeck, as per Bloomberg, is pursuing endocrine- and neurology-focused Xeris Biopharma, whose market cap is c.28% of that of Lundbeck. Considering ...